INTRODUCTION
============

Machado-Joseph disease, also known as spinocerebellar ataxia type 3 (MJD/SCA3), is an autosomal dominant neurodegenerative disorder that is characterized by progressive cerebellar ataxia and pyramidal signs, which can be associated with a complex clinical picture and includes extrapyramidal signs or amyotrophy \[[@r1], [@r2]\]. MJD is caused by an abnormal CAG trinucleotide repeat expansion in exon 10 of the ataxin-3 gene (*ATXN3*), located at 14q32.1. Deleterious expansions (CAG~exp~) consensually contain 61 to 87 CAG repeats, whereas wild type alleles (CAG~nor~) range from 12 to 44 \[[@r2]\].

As with other diseases caused by repeat expansions, such as Huntington's disease (HD) and other spinocerebellar ataxias, there is an inverse correlation between expanded repeat size and the age at which pathogenesis leads to disease onset \[[@r3]\]. Depending on the cohort structure, the size of the repeat expansion explains 55 to 70% of the age at onset (AO) variability in MJD, suggesting the existence of additional modifying factors \[[@r3], [@r4]\]. Although several genetic factors have been proposed as modifiers, such as CAG repeat size of normal *ATXN3* (SCA3), *HTT* (HD), *ATXN2* (SCA2) and *ATN1* (DRPLA) alleles, *APOE* status, and expression level of *HSP40* \[[@r4]--[@r6]\], these were not replicated by subsequent studies \[[@r7], [@r8]\]. Since CAG tract profile and allelic frequencies of the potential modifier loci can have unique characteristics in different populations, large collaborative studies are required to identify genetic modifiers in MJD, as well as replicate the findings of such studies \[[@r8]\].

Previously, Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium carried out a GWA approach of HD individuals to reveal genetic modifiers of AO in HD \[[@r9], [@r10]\]. A total of eleven \[[@r9]\] and fourteen loci \[[@r10]\] were found to be associated with residual age at HD onset. In the present study, we performed the first GWAS to identify some possible genetic modifiers of AO in MJD. First, we assessed the relationship between AO and size of the expanded (CAG~exp~) and normal (CAG~nor~) alleles, biological sex and geographical origin. Next, we determined a residual AO for each subject, which is the difference between the measured AO and the predicted/estimated AO from expanded CAG repeat size alone. Using the residuals as a quantitative phenotype for a GWAS, we looked for genetic factors that modulate AO in MJD.

RESULTS
=======

The inverse correlation between CAG~exp~ and age at onset
---------------------------------------------------------

In the first phase of the study, the expanded *ATXN3*-CAG repeat lengths of 786 MJD patients were assessed. The mean (SD) CAG~exp~ size were Australia: 68.2 (±3.3), Brazil: 74.3 (3.9), Germany: 72.9 (±3.6), North America: 73 (±4.3) and Portugal: 72 (±4.0). Next, the relationship between AO and CAG~exp~ size, CAG~nor~ size, sex and ethnicity was examined ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}). The previously observed negative correlation between *ATXN3* CAG~exp~ size and AO \[[@r3]\] was confirmed (Pearson's correlation coefficient R^2^ = 0.62) ([Figure 1](#f1){ref-type="fig"}). The CAG~nor~ size (P = 0.39), sex (P = 0.02) and geographic origin (P \[Brazil\] = 0.38, P \[Germany\] = 0.38, P \[North America\] = 0.33, P \[Portugal\] = 0.29) were not significant and their addition had little contribution to the model (ΔR^2^ = 0.0072). Residual AO for each sample was calculated and used as a quantitative phenotype to identify the modifiers of AO. The distribution of residual AO was close a theoretical normal distribution ([Figure 1](#f1){ref-type="fig"}).

![**The inverse correlation between CAG~exp~ and AO (left) and the distribution of residual AO (right) observed in our MJD cohort.**](aging-12-102825-g001){#f1}

Genome-wide association study
-----------------------------

After post-imputation quality assessments, a total of 700 individuals with genotyping information for 6,716,580 variants remained for GWAS. The Manhattan plots are shown in [Figure 2](#f2){ref-type="fig"}. The genomic inflation factor was close to one (λ = 0.98), indicating the p-values were not inflated. Genome-wide suggestive associations (P \< 1 × 10^−5^) with 204 variants across 9 loci were identified ([Supplementary Table 3](#SD3){ref-type="supplementary-material"}). The most significantly associated SNP at each locus are shown in [Table 1](#t1){ref-type="table"}. Positional gene mapping aligned SNPs to 17 genes by their genomic location. Fourteen of the 204 variants had a Combined Annotation Dependent Depletion (CADD)-PHRED score higher than the suggested threshold for deleterious SNPs (12.37), arguing the given loci have a functional role \[[@r11]\].

![**Manhattan plot of the GWAS for residual AO of MJD.** Imputed using the HRC panel, 6,716,580 variants that passed QC are included in the plot. The x-axis shows the physical position along the genome. The y-axis shows the −log~10~(p-value) for association. The red line indicates the level of genome-wide suggestive association (*P* = 1 × 10^−5^).](aging-12-102825-g002){#f2}

###### Suggestive loci associated with residual age at onset in MJD. Chr: chromosome, MAF: minor allele frequency, 1KGP: 1000 Genomes Project.

  ------------- --------- ----------------------- ------------------------------- ------------------ ------------------ ------------- -------------- -------------------- ---------------
  **SNP**       **Chr**   **Position (GRCh37)**   **Nearest gene**                **Minor allele**   **Major allele**   **MJD MAF**   **1KGP MAF**   **b (SNP effect)**   **P-value**
  rs62171220    2         137802855               *THSD7B*                        G                  C                  0.13          0.11           2.71                 4.45 × 10^−6^
  rs2067390     2         191209028               *HIBCH, INPP1*                  A                  T                  0.04          0.06           4.74                 6.39 × 10^−6^
  rs144891322   5         85135387                *RPL5P17,*                      C                  T                  0.02          0.007          6.10                 5.18 × 10^−6^
  rs11529293    11        36855388                *C11orf74, RAG1, RAG2*          T                  C                  0.14          0.26           -2.71                3.30 × 10^−6^
  rs7480166     11        42984753                *HNRNPKP3*                      A                  G                  0.40          0.40           -1.86                4.17 × 10^−6^
  rs585809      11        119949979               *TRIM29*                        T                  C                  0.06          0.17           -3.76                9.50 × 10^−6^
  rs72660056    13        113507543               *ATP11A*                        A                  G                  0.08          0.05           -3.29                3.94 × 10^−6^
  rs11857349    15        99924857                *TTC23, SYNM, LRRC28*           G                  A                  0.04          0.02           -4.58                3.43 × 10^−6^
  rs8141510     22        42821185                *NFAM1, CYP2D6, NAGA, NDUFA6*   C                  T                  0.43          0.49           1.83                 3.94 × 10^−6^
  ------------- --------- ----------------------- ------------------------------- ------------------ ------------------ ------------- -------------- -------------------- ---------------

Interaction analysis between CAG~exp~, sex and SNP genotype
-----------------------------------------------------------

To assess a possible interaction between CAG~exp~ size and the variants identified, each of the nine variants was added to the initial linear regression, modelling AO as a function of CAG~exp~ size, SNP, sex, the first three principal components, CAG~nor~ size, interactions of SNP:CAG~exp~ and SNP:sex. Association of each independent SNP with AO revealed nominally significant p-values (P \[rs7480166\] = 8.42 × 10^−6^, P \[rs62171220\] = 6.33 × 10^−3^, P \[rs2067390\] = 4.51 × 10^−5^, P \[rs144891322\] = 1.14 × 10^−5^, P \[rs11529293\] = 1.62 × 10^−5^, P \[rs585809\] = 2.91 × 10^−5^, P \[rs72660056\] = 1.66 × 10^−3^, P \[rs11857349\] = 8.21 × 10^−6^, P \[rs8141510\] = 1.33 × 10^−3^). With the addition of the identified variants to the model, correlation coefficient R^2^ increased to 0.71 (ΔR^2^ = 0.082). Among the nine variants, only rs585809 (mapped to *TRIM29*) had a significant interaction with CAG~exp~ (P = 0.01), suggesting that rs585809 might modulate AO through this epistatic interaction on CAG~exp~. The addition of SNP:sex interaction had little contribution to the model (ΔR^2^ = 0.005).

Association of HD-AO modifier variants in MJD
---------------------------------------------

Association of previously identified HD-AO modifier loci in MJD were assessed. Among the 25 HD-AO modifier variants in 17 loci, a total of 18 variants (MAF \> 0.02) in 12 loci were tested in this study ([Supplementary Table 4](#SD4){ref-type="supplementary-material"}). None of these HD-AO modifiers reached the genome-wide suggestive threshold. However, two variants rs144287831 (*P* = 0.02, effect size = - 0.98) and rs1799977 (*P* = 0.02, effect size = - 0.98) in the *MLH1* locus were found to be nominally associated with a later AO in MJD.

Pathway and gene-set enrichment analysis
----------------------------------------

A gene-set enrichment and pathway analysis was conducted using i-GSEA4GWAS v2 \[[@r12]\]. Various approaches and algorithms are currently in use to conduct similar analyses. To be able to make better comparisons with other studies that may use different approaches, we performed a secondary gene-set enrichment and pathway analysis using the VEGAS2 \[[@r13]\] and PASCAL \[[@r14]\] software ([Supplementary Tables 5](#SD2){ref-type="supplementary-material"}--[7](#SD6){ref-type="supplementary-material"}). We also used these results for replication purposes in our own study. A total of 13 overrepresented pathways were found, after FDR-multiple testing correction (q-value \< 0.05) in the primary GSEA analysis and replicated using at least one of the secondary gene-set enrichment algorithms ([Table 2](#t2){ref-type="table"}). Overall, the most significantly enriched gene-sets and pathways were vesicle transport, olfactory signaling, and synaptic pathways. Visualization and clustering of pathways are shown in [Figure 3](#f3){ref-type="fig"}.

###### Pathways significant after multiple-correction (q \< 5 x 10^-2^) in the primary GSEA analysis and replicated using at least one of the secondary gene-set enrichment algorithms. NA means that the pathway was not enriched by at least two significant genes in VEGAS.

  -------------- --------------------------------------- -------------------- -------------------- --------------------- ------------------------------ ----------------------
  **Pathway**    **Description**                         **p-value (GSEA)**   **q-value (GSEA)**   **p-value (VEGAS)**   **permuted p-value (VEGAS)**   **p-value (PASCAL)**
  GO:0030133     transport vesicle                       \< 1.0 x 10^-3^      8.20 x 10^-3^        6.15 x 10^-40^        4.46 x 10^-1^                  6.70 x 10^-3^
  KEGG:04740     olfactory transduction                  \< 1.0 x 10^-3^      8.30 x 10^-3^        NA                    NA                             3.89 x 10^-4^
  R-HSA:381753   olfactory signaling pathway             \< 1.0 x 10^-3^      8.80 x 10^-3^        1.10 x 10^-27^        7.71 x 10^-1^                  2.51 x 10^-4^
  GO:0044456     synapse part                            \< 1.0 x 10^-3^      9.30 x 10^-3^        1.25 x 10^-182^       \< 1.0 x 10^-6^                \< 1.0 x 10^-7^
  R-HSA:74217    purine salvage                          \< 1.0 x 10^-3^      1.06 x 10^-2^        1.06 x 10^-2^         2.15 x 10^-1^                  6.48 x 10^-3^
  GO:0045202     synapse                                 \< 1.0 x 10^-3^      1.15 x 10^-2^        1.15 x 10^-2^         \< 1.0 x 10^-6^                \< 1.0 x 10^-7^
  GO:0004177     aminopeptidase activity                 \< 1.0 x 10^-3^      1.50 x 10^-2^        1.50 x 10^-2^         3.41 x 10^-1^                  1.24 x 10^-2^
  GO:0008238     exopeptidase activity                   \< 1.0 x 10^-3^      1.80 x 10^-2^        1.80 x 10^-2^         2.80 x 10^-2^                  8.31 x 10^-3^
  GO:0006898     receptor mediated endocytosis           \< 1.0 x 10^-3^      2.25 x 10^-2^        2.25 x 10^-2^         2.03 x 10^-1^                  6.64 x 10^-3^
  GO:0016917     GABA receptor activity                  \< 1.0 x 10^-3^      2.26 x 10^-2^        2.26 x 10^-2^         1.30 x 10^-4^                  2.30 x 10^-5^
  GO:0030140     trans Golgi network transport vesicle   \< 1.0 x 10^-3^      2.36 x 10^-2^        2.36 x 10^-2^         2.80 x 10^-2^                  1.28 x 10^-1^
  GO:0009725     response to hormone stimulus            \< 1.0 x 10^-3^      2.73 x 10^-2^        2.73 x 10^-2^         1.32 x 10^-1^                  1.30 x 10^-4^
  GO:0030425     Dendrite                                \< 1.0 x 10^-3^      3.86 x 10^-2^        3.86 x 10^-2^         \< 1.0 x 10^-6^                \< 1.0 x 10^-7^
  -------------- --------------------------------------- -------------------- -------------------- --------------------- ------------------------------ ----------------------

![**Visualization of the gene-sets and pathways enriched in primary GSEA analysis** (**A**) and replicated in VEGAS and PASCAL (**B**). The size of the nodes corresponds to the number of the genes associated with a term. The significance is represented by the color of the nodes (*P* \< 0.05, 0.05 \< *P* \< 0.1 and *P* \> 0.1 are represented by red, yellow and gray, respectively).](aging-12-102825-g003){#f3}

DISCUSSION
==========

Using five cohorts from different geographical origins, we performed the first GWAS to examine the presence of genetic factors that could modify AO in MJD. We identified a total of nine loci that were potentially associated with either an earlier or later AO. Concomitantly, we confirmed the previously observed negative correlation between CAG~exp~ and AO \[[@r3]\]. It was shown previously that normal *ATXN3* allele (CAG~nor~) had a significant influence on AO of MJD \[[@r15]\]; however, several studies did not replicate this effect \[[@r6], [@r8]\]. Indeed, we did not observe an association between CAG~nor~ and AO. However, it had little contribution to our model, with a minor difference in the correlation coefficient (ΔR^2^ = 0.0012).

In our GWAS, the strongest signal is for the rs11529293 variant (*P* = 3.30 × 10^-6^) within the *C11orf72* and *RAG* loci at 11p12. Within this locus, two *RAG* genes, recombination-activating genes *RAG1* and *RAG2*, were shown to be implicated in DNA damage response and DNA repair machineries \[[@r16], [@r17]\]. The rs585809 variant, which was mapped to the *TRIM29* gene, was found to interact with CAG~exp~, suggesting that it might have an effect on AO through this interaction. Both *RAG* and *TRIM29* loci were identified as AO-hastening modifiers. *TRIM29* encodes for tripartite motif protein 29, which is implicated in mismatch repair and double strand breaks pathways \[[@r18], [@r19]\]. TRIM29 is involved both upstream and downstream of these pathways, in the regulation of DNA repair proteins into chromatin by mediating the interaction between them. One of these DNA repair proteins is MLH1, which is implicated in mismatch repair complex \[[@r19]\]. Previously, the *MLH1* locus was identified as an AO modifier in another neurodegenerative disease caused by CAG repeat expansion, Huntington's disease \[[@r9], [@r10], [@r20]\]. Additionally, in a genome-wide genetic screening study, MLH1-knock out was shown to modify the somatic expansion of the CAG repeat and slow the pathogenic process in HD mouse model \[[@r21]\]. Overall, the association of *TRIM29* and *RAG* loci suggests that DNA repair mechanisms may be implicated in the alteration of AO of MJD, as well as HD, and may have a role in the pathogenesis of other CAG repeat diseases. Interestingly, in a previous study, we found variants in three transcription-coupled repair genes (ERCC6, RPA, and CDK7) associated with different CAG instability patterns in MJD \[[@r22]\].

We identified gene-sets enriched in olfactory signaling, vesicle transport, and synaptic pathways. Olfactory dysfunction is one of the main non-motor symptoms that was already described in patients with MJD \[[@r23], [@r24]\]. In a previous study, transplantation of olfactory ensheathing cells, which are specialized glial cells of the primary olfactory system, were found to improve motor function in an MJD mice model, and were suggested as a novel potential strategy for MJD treatment \[[@r25]\]. Vesicle transport and synaptic pathways were also implicated in MJD, as well as in other neurodegenerative diseases \[[@r26], [@r27]\]. An interruption of synaptic transmission caused by an expanded polyglutamine repeat and mutant ataxin-3 aggregates were shown in *Drosophila* and *Caenorhabditis elegans* models of MJD. Therefore, the interaction between synaptic vesicles and mutant aggregates supports the role of synaptic vesicle transport in the pathogenesis of MJD \[[@r28], [@r29]\]. Overall, we suggest that these gene-sets and pathways might construct a larger molecular network that could modulate the AO in MJD.

In summary, our study identified nine genetic loci that may modify the AO of MJD. Identification of *TRIM29* and *RAG* genetic variants, as well as our gene-set enrichment analyses, implicated DNA repair, olfactory signaling, synaptic, and vesicle transport pathways in the pathogenesis of MJD. Although we used different cohorts from five distinct geographical ethnicities, a replication study in similar or additional populations would add valuable evidence to support our findings.

MATERIALS AND METHODS
=====================

Study subjects
--------------

A total of 786 MJD patients from five distinct geographical origins (Portugal, Brazil, North America, Germany and Australia) were included in the present study. The overall average age at onset (standard deviation) was 38 (± 1.82) years, with a 1:1 male to female ratio. All subjects provided informed consent, and the study was approved by the respective institutional review boards. Detailed cohort demographics are shown in [Supplementary Table 2](#SD2){ref-type="supplementary-material"}.

Assessment of the *ATXN3* CAG repeat length
-------------------------------------------

A singleplex polymerase chain reaction was performed to determine the length of the CAG~exp~ and CAG~nor~ alleles at exon 10 of *ATXN3* \[[@r30]\]. The final volume for each assay was 10 μL: 7.5 ng of gDNA, 0.2 μM of each primer, 5 μL of Taq PCR Master Mix Kit Qiagen®, 1 μL of Q-Solution from Qiagen® and H~2~O. Fragment length analysis was done using ABIPrism 3730xl sequencer (Applied Biosystems®, McGill University and Genome Québec Innovation Centre) and GeneMapper software \[[@r31]\]. A stepwise regression model was performed to assess the correlation between AO and CAG~exp~ size, as well as gender, origin, CAG~nor~ size, and interaction between these variables. Residual AO was calculated for each subject by subtracting individual's expected AO based upon CAG~exp~ size from actual AO, to be used as the primary phenotype for following genetic approach.

Genotyping, quality control and imputation
------------------------------------------

Samples were genotyped using the Global Screening Array v.1.0 from Illumina (636,139 markers). Sample-based (missingness, relatedness, sex, and multidimensional scaling analysis) and SNP-based quality assessments (missingness, Hardy-Weinberg equilibrium, and minor allele frequency) were conducted using PLINK version 1.9 \[[@r32]\]. In sample level QC, samples were excluded with one or more of the following: high missingness (missingness rate \> 0.05), close relationship (pi-hat value \> 0.2), discrepancy between genetically-inferred sex and reported sex, population outliers (deviation ≥ 4 SD from the population mean in multidimensional scaling analysis). All SNPs were checked for marker genotyping call rate (\> 98%), minor allele frequency (MAF) \> 0.05, and HWE (p-value threshold = 1.0 × 10^-5^).

Phasing and imputation were performed using SHAPEIT \[[@r33]\] and PBWT \[[@r34]\] pipelines, implemented on the Sanger Imputation Service \[[@r35]\]. Haplotype Reference Consortium (HRC) reference panel r1.1 containing 64,940 human haplotypes at 40,405,505 genetic markers were used as the reference panel. Imputed variants with an allele count of 30 (MAF \> 0.02), an imputation quality score above 0.3 and an HWE p-value of \> 1.0 × 10^-5^ were included for subsequent analysis.

Genome-wide association analysis
--------------------------------

A genome-wide linear mixed model based association analysis was conducted using --mlma-loco option of GCTA version 1.91.7 \[[@r36]\]. Residual AO was modelled as a function of minor allele count of the test SNP, sex, and the first three principal components based on the scree plot ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Manhattan plots were generated in FUMA v.1.3.4 \[[@r37]\]. Regional association plots were generated using LocusZoom \[[@r38]\] ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

Functional annotation of SNPs
-----------------------------

Genomic risk loci were defined using SNP2GENE function implemented in FUMA. Independent suggestive SNPs (*P* \< 1 × 10^−5^) with a threshold of r^2^ \< 0.6 were selected within a 250 kb window. The UK Biobank release 2 European population consisting of randomly selected 10,000 subjects was used as the reference population panel. The ANNOVAR \[[@r39]\] categories and combined annotation-dependent depletion (CADD) \[[@r40]\] scores were obtained from FUMA for functional annotation. Functionally annotated variants were mapped to genes based on genomic position using FUMA positional mapping tool.

Pathway analysis
----------------

To identify known biological pathways and gene sets at the associated loci, an enrichment approach was applied using public datasets containing Gene Ontology (GO, <http://geneontology.org>), the Kyoto Encyclopaedia of Genes and Genomes (KEGG, <https://www.genome.jp/kegg>) and Reactome (<https://reactome.org>) pathways. The primary enrichment analysis was performed using the i-GSEA4GWAS v2. It uses a candidate list of a genome-wide set of genes mapped within the SNP loci and ranks them based on the strength of their association with the phenotype. Genes were mapped within 20 kb up or downstream of the SNPs with a *P* \< 0.05. Gene and pathway sets meeting a false discovery rate *(FDR)*-corrected *q*-value \< 0.05 were regarded as significantly associated with high confidence, and *q*-value \< 0.25 was regarded to be possibly associated with the phenotype of interest. We performed a secondary gene-based association test using the Versatile Gene-based Association Study (VEGAS) algorithm that controls the number of SNPs in each gene and the linkage disequilibrium (LD) between these SNPs using the HapMap European population. As a third algorithm to identify enriched pathways, we used Pathway Scoring Algorithm (PASCAL), which controls for potential bias from gene size, SNP density, as well as LD. ClueGO \[[@r41]\] and CluePedia \[[@r42]\] plug-ins in Cytoscape were employed to visualize identified pathways and their clustering.
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